文献速递临床试验与 GCP

冻存封装多供体粪便滤液治疗活动性溃疡性结肠炎(FRESCO):前瞻性、多中心、双盲、随机对照试验研究方案

Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial.
PubMed 文献 · Trials · 2022-02-22

FRESCO是一项前瞻性、多中心、双盲、三臂随机对照试验,计划纳入174例轻中度活动性溃疡性结肠炎患者,比较重复长期多供体粪便微生物群(FM)或粪便微生物群滤液(FMF)口服冻存胶囊与安慰剂的安全性和疗效,主要结局为第12周临床缓解。

要点

  • FRESCO为前瞻性、多中心、双盲、三臂随机对照试验,计划纳入174例轻中度活动性UC患者。
  • 试验比较重复长期多供体FM或FMF口服冻存胶囊与安慰剂,主要结局为第12周临床缓解。
  • 研究同时评估FMT和FMFT的短期与长期安全性及微生物和免疫学变化。

核心结论

  • 该研究方案旨在评估封装FM和FMF移植治疗轻中度UC的疗效、FMT和FMFT的短期与长期安全性,以及FMT和FMFT后发生的微生物和免疫学变化。

研究设计与样本

  • 前瞻性、多中心、双盲、三臂随机对照试验,计划随机纳入174例轻中度活动性UC患者。
  • 干预为重复长期多供体FM或FMF口服冻存胶囊移植,对照为安慰剂。
  • 主要结局为第12周临床缓解。
  • 试验注册号:ClinicalTrials.gov NCT03843385;DRKS DRKS00020471。

主要发现

  • 背景指出,UC和复发性艰难梭菌感染(CDI)的随机对照试验已确立FMT为有效疗法。
  • 初步结果显示,供体粪便的无菌粪便微生物群滤液(<0.2 μm;FMF、FMFT)移植也可驱动CDI患者胃肠道微生物群变化并消除症状。
  • 监管机构在FMT成功应用的同时,因FMT传播肠道病原体导致严重不良事件的报告而发出安全性警示。
  • 为降低风险,研究建立了针对供体的广泛检测方案和所生产胶囊的检疫规定,但认为需要替代概念。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant morbidity and mortality. Although the precise cause remains unknown, disturbances in the intestinal microbial community have been linked to its pathogenesis. Randomized controlled trials in UC and relapsing Clostridioides difficile infection (CDI) have established fecal microbiota (FM) transfer (FMT) as an effective therapy. In this context, preliminary results indicated that the transfer of sterile fecal microbiota filtrates (<0.2 μm; FMF, FMFT) of donor stool also drives gastrointestinal microbiota changes and eliminates symptoms in CDI patients. However, along with the success of FMT, regulatory agencies issued safety alerts following reports of serious adverse events due to transmission of enteric pathogens through FMT. To reduce this risk, we established an extensive test protocol for our donors and quarantine regulations for the produced capsules, but alternative concepts are desirable. METHODS: Our project is a randomized, controlled, longitudinal, prospective, three-arm, multicenter, double-blind study to determine the safety and efficacy of repeated long-term, multi-donor FM or FMF transfers compared to placebo using oral, frozen capsules in 174 randomized patients with mild to moderate active UC. The primary outcome will be clinical remission at week 12. DISCUSSION: This proposal aims to examine (a) the efficacy of encapsulated transfer of FM and FMF as a therapy for mild to moderate UC, (b) the short- and long-term safety of FMT and FMFT in patients with UC, and (c) the microbial and immunologic changes that occur after FMT and FMFT to help understand how and why it affects inflammatory bowel disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT03843385 . DRKS (Deutsches Register für Klinische Studien) DRKS00020471.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Stallmach A, Grunert P, Stallhofer J, et al. Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials. 2022. PMID: 35193638. doi:10.1186/s13063-022-06095-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。